Free Trial
NASDAQ:DBVT

DBV Technologies (DBVT) Stock Price, News & Analysis

DBV Technologies logo
$9.85 +0.38 (+4.01%)
Closing price 06/18/2025 04:00 PM Eastern
Extended Trading
$9.77 -0.08 (-0.77%)
As of 06/18/2025 07:48 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About DBV Technologies Stock (NASDAQ:DBVT)

Key Stats

Today's Range
$9.20
$10.06
50-Day Range
$7.32
$11.48
52-Week Range
$2.20
$12.78
Volume
34,150 shs
Average Volume
190,309 shs
Market Capitalization
$269.79 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$14.75
Consensus Rating
Moderate Buy

Company Overview

DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis. The company's earlier stage research programs includes vaccine for the respiratory syncytial virus, potential treatments for inflammatory bowel disease, celiac disease, and type I diabetes. In addition, it develops Viaskin technology platform, a platform to potentially treat food allergy. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France.

DBV Technologies Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
68th Percentile Overall Score

DBVT MarketRank™: 

DBV Technologies scored higher than 68% of companies evaluated by MarketBeat, and ranked 970th out of 2,787 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    DBV Technologies has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 3 buy ratings, no hold ratings, and 1 sell rating.

  • Amount of Analyst Coverage

    DBV Technologies has only been the subject of 4 research reports in the past 90 days.

  • Read more about DBV Technologies' stock forecast and price target.
  • Earnings Growth

    Earnings for DBV Technologies are expected to grow in the coming year, from ($7.05) to ($5.45) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of DBV Technologies is -2.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of DBV Technologies is -2.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    DBV Technologies has a P/B Ratio of 6.94. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about DBV Technologies' valuation and earnings.
  • Percentage of Shares Shorted

    0.08% of the float of DBV Technologies has been sold short.
  • Short Interest Ratio / Days to Cover

    DBV Technologies has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in DBV Technologies has recently decreased by 78.36%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    DBV Technologies does not currently pay a dividend.

  • Dividend Growth

    DBV Technologies does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    0.08% of the float of DBV Technologies has been sold short.
  • Short Interest Ratio / Days to Cover

    DBV Technologies has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in DBV Technologies has recently decreased by 78.36%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    DBV Technologies has a news sentiment score of 0.44. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.69 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 3 news articles for DBV Technologies this week, compared to 2 articles on an average week.
  • Search Interest

    3 people have searched for DBVT on MarketBeat in the last 30 days. This is an increase of 50% compared to the previous 30 days.
  • MarketBeat Follows

    1 people have added DBV Technologies to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, DBV Technologies insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $730.00 in company stock.

  • Percentage Held by Insiders

    Only 1.44% of the stock of DBV Technologies is held by insiders.

  • Percentage Held by Institutions

    71.74% of the stock of DBV Technologies is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about DBV Technologies' insider trading history.
Receive DBVT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for DBV Technologies and its competitors with MarketBeat's FREE daily newsletter.

DBVT Stock News Headlines

Why the Pentagon has its eye on Utah...
There's a strange bidding war underway in Utah... Smack in the middle of Utah's Black Desert...The U.S. government is holding record land auctions. Why? Because it turns out America has access to a powerful new form of energy – not gas, oil, or uranium – that's buried deep beneath U.S. soil. This abundant new power source is so plentiful... the U.S. Department of Energy says it could fuel the entire U.S. economy uninterrupted for the next 2 million years. If not longer.
See More Headlines

DBVT Stock Analysis - Frequently Asked Questions

DBV Technologies' stock was trading at $3.09 on January 1st, 2025. Since then, DBVT shares have increased by 218.8% and is now trading at $9.85.
View the best growth stocks for 2025 here
.

DBV Technologies S.A. (NASDAQ:DBVT) issued its quarterly earnings results on Friday, April, 11th. The company reported ($1.10) earnings per share (EPS) for the quarter. The business earned $0.51 million during the quarter. DBV Technologies had a negative net margin of 3,249.99% and a negative trailing twelve-month return on equity of 278.24%.

Shares of DBV Technologies reverse split on the morning of Friday, November 29th 2024. The 1-5 reverse split was announced on Monday, November 11th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, November 28th 2024. An investor that had 100 shares of stock prior to the reverse split would have 20 shares after the split.

Shares of DBVT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that DBV Technologies investors own include Meta Platforms (META), Pfizer (PFE), Novavax (NVAX), NVIDIA (NVDA), OPKO Health (OPK), Gilead Sciences (GILD) and Sorrento Therapeutics (SRNE).

Company Calendar

Last Earnings
4/11/2025
Today
6/20/2025
Next Earnings (Estimated)
7/29/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:DBVT
Employees
80
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$14.75
High Stock Price Target
$21.00
Low Stock Price Target
$7.25
Potential Upside/Downside
+49.7%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
4 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$113.92 million
Net Margins
-3,249.99%
Pretax Margin
-3,249.79%

Debt

Sales & Book Value

Annual Sales
$4.15 million
Price / Cash Flow
N/A
Book Value
$1.42 per share
Price / Book
6.94

Miscellaneous

Free Float
26,996,000
Market Cap
$269.79 million
Optionable
Optionable
Beta
-0.63
Reduce the Risk Cover

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

This page (NASDAQ:DBVT) was last updated on 6/20/2025 by MarketBeat.com Staff
From Our Partners